文献速递其他结缔组织病血管炎

注意缺陷多动障碍(ADHD)治疗用中枢神经兴奋剂与雷诺现象关联的范围综述

Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud's phenomenon: A scoping review.
PubMed 文献 · Semin Arthritis Rheum · 2021-09-16

该范围综述检索PubMed数据库(1951-11-01至2020-08-01),纳入9篇文献共70例患者,探讨治疗ADHD的中枢神经兴奋剂与雷诺现象(RP)及外周血管病变的关联。报告的药物包括哌甲酯、右苯丙胺、托莫西汀和赖氨酸安非他明,部分病例在停药后RP症状完全缓解,另有不可逆缺血并发症及潜在自身免疫关联的报道。

要点

  • ADHD中枢兴奋剂可能诱发或加重雷诺现象及外周血管病变。
  • 部分病例停药后RP症状完全缓解,也可减量或换药处理。
  • 已有指端自体截肢等不可逆缺血并发症及潜在自身免疫关联报道。

核心结论

  • 治疗ADHD的中枢神经兴奋剂与雷诺现象及外周血管病变存在关联,但现有文献有限,需未来研究进一步明确。

研究设计与样本

  • 范围综述,检索PubMed数据库(1951-11-01至2020-08-01)英文文献,最终纳入9篇文献共70例患者。

主要发现

  • 外周血管表现包括新发或加重的雷诺现象发作及冷敏感(肢端发绀和冻疮)。
  • 已报告不可逆缺血并发症,包括指端自体截肢和下肢危重性指端缺血。
  • 涉及药物为哌甲酯(n=5)、右苯丙胺(n=4)、托莫西汀(n=2)和赖氨酸安非他明(n=2)。
  • 半数研究(n=5)观察到停药后RP症状完全缓解。
  • 其他治疗策略包括减量和换用替代药物,并有药物诱导自身免疫及新发系统性硬化症的推测性关联报道。

临床怎么用

  • 对使用ADHD中枢兴奋剂的患者应关注雷诺现象及外周血管病变症状。
  • 出现相关血管症状时可考虑停药、减量或换用替代药物治疗。

局限性

  • 现有文献数量有限,仅纳入9篇文献共70例患者,关联性仍需未来研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The association between central nervous (CNS) stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud's phenomenon (RP) has received little attention to date. Our aim was to map the existing literature on aetiopathogenesis, clinical presentation and management of peripheral vasculopathy, with a focus on RP, secondary to drug therapy for ADHD. We searched the PubMed® database (01/11/1951 to 01/08/2020) and included articles written in English, which focussed on CNS stimulants used to treat ADHD and RP. The search identified 150 articles 9 of which were eligible for inclusion (70 patients). The majority of studies (n = 6) related to children or adolescents; however, adult cases were also identified. Peripheral vascular manifestations included attacks of RP (new and worsening) and cold sensitivity (acrocyanosis and perniosis). Irreversible ischaemic complications including digital autoamputation and lower limb critical digital ischaemia have also been reported. The implicated causative CNS stimulants were Methylphenidate (n = 5), Dextroamphetamine (n = 4), Atomoxetine (n = 2), and Lisdexamphetamine (n = 2). Complete resolution of RP symptoms was observed in half (n = 5) of studies upon drug cessation. Other therapeutic strategies have included dose reduction and switching to an alternative drug therapy. A potential autoimmune association has also been postulated including drug-induced autoimmunity and new cases of systemic sclerosis which have been potentially attributed to treatment. Future research is required to understand the association between CNS stimulant drug therapies for ADHD and peripheral vascular manifestations, including RP.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Umair HM, Sandler RD, Alunno A, et al. Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud's phenomenon: A scoping review. Semin Arthritis Rheum. 2021. PMID: 34655948. doi:10.1016/j.semarthrit.2021.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。